MINT-ACYCLOVIR TABLET
Country: Kanada
Lingwa: Ingliż
Sors: Health Canada
Karatteristiċi tal-prodott
(SPC)
21-01-2022
Xi dokumenti għal dan il-prodott mhumiex disponibbli bħalissa, tista 'tibgħat talba lis-servizz tal-konsumatur tagħna u aħna ninnotifikawkom malli nkunu nistgħu niksbuhom.
Ibgħat talba.
Ibgħat talba.
Ingredjent attiv:
ACYCLOVIR
Disponibbli minn:
MINT PHARMACEUTICALS INC
Kodiċi ATC:
J05AB01
INN (Isem Internazzjonali):
ACYCLOVIR
Dożaġġ:
200MG
Għamla farmaċewtika:
TABLET
Kompożizzjoni:
ACYCLOVIR 200MG
Rotta amministrattiva:
ORAL
Unitajiet fil-pakkett:
15G/50G
Tip ta 'preskrizzjoni:
Prescription
Sommarju tal-prodott:
Active ingredient group (AIG) number: 0115506002; AHFS:
L-istatus ta 'awtorizzazzjoni:
APPROVED
Data ta 'l-awtorizzazzjoni:
2022-01-25
Karatteristiċi tal-prodott
PRODUCT MONOGRAPH
PR
MINT-ACYCLOVIR
ACYCLOVIR TABLETS USP
200 MG, 400 MG AND 800 MG
ANTIVIRAL AGENT
MINT PHARMACEUTICALS INC.
DATE OF PREPARATION:
6575 DAVAND DRIVE
JANUARY 21, 2022
MISSISSAUGA, ONTARIO
L5T 2M3
Control No. 239932
_MINT-ACYCLOVIR Product Monograph_
_ _
_Page 2 of 37 _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.................................................. 3 SUMMARY PRODUCT
INFORMATION........................................................................
3
INDICATIONS AND CLINICAL USE
.............................................................................
3
CONTRAINDICATIONS
.................................................................................................
4
WARNINGS AND
PRECAUTIONS.................................................................................
4
ADVERSE REACTIONS
.................................................................................................
6
DRUG INTERACTIONS
..................................................................................................
9
DOSAGE AND ADMINISTRATION
...............................................................................
9
OVERDOSAGE
..............................................................................................................11
ACTION AND CLINICAL PHARMACOLOGY
.............................................................12
STORAGE AND STABILITY
.........................................................................................14
DOSAGE FORMS, COMPOSITION AND PACKAGING
...............................................14
PART II: SCIENTIFIC
INFORMATION.......................................................................
15
PHARMACEUTICAL INFORMATION
..........................................................................15
CLINICAL TRIALS
........................................................................................................15
DETAILED PHARMACOLOGY
....................................................................................16
VIR
Aqra d-dokument sħiħ
